SCHEMBL16747879

SCHEMBL16747879

Cc1cn2cc(F)cc(F)c2n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 1/20 0.40
TLR8 Q9NR97 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
GRM5 P41594 7/20 0.36
GAA P10253 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HTT P42858 1/20 0.31
CYP11B2 P19099 2/20 0.31
CYP11B1 P15538 1/20 0.31
MAPK1 P28482 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
MAPT P10636 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24586512 0.84 RXFP1 (0.40) TLR9TLR8TLR7GRM5L3MBTL1
SCHEMBL24163731 0.84 GRM5 (0.42) TLR9TLR8TLR7GRM5HTT
SCHEMBL23571402 0.81 RXFP1 (0.35) TLR9TLR8TLR7GRM5RXFP1
SCHEMBL31204411 0.81 TLR9 (0.39) TLR9TLR8TLR7GRM5HTT
SCHEMBL15068755 0.81 RXFP1 (0.41) TLR9TLR8TLR7GRM5L3MBTL1
SCHEMBL16339165 0.81 TLR9 (0.41) TLR9TLR8TLR7GRM5HTT
SCHEMBL25151848 0.81 TLR9 (0.39) TLR9TLR8TLR7GRM5HTT
Hydrochloric Acid SCHEMBL29256940 0.79 TLR9 (0.41) TLR9TLR8TLR7GRM5HTT
Hydrochloric Acid SCHEMBL16339034 0.79 TLR9 (0.41) TLR9TLR8TLR7GRM5HTT
Bromide SCHEMBL30426544 0.79 RXFP1 (0.41) TLR9TLR8TLR7GRM5L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B TLR9 3228/4885TLR8 3289/4885TLR7 3172/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B TLR9 3228/4885TLR8 3289/4885TLR7 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.